FindTrial
Sign In

imatinib mesilate

DRUG3 trials

Sponsors

Ascentage Pharma Group Inc., Novartis Pharmaceuticals

Conditions

Chronic Myelogenous LeukemiaNewly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Refractory Desmoplastic Small Round Cell Tumors

Phase 1

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
CompletedNCT00417807
Novartis PharmaceuticalsRefractory Desmoplastic Small Round Cell Tumors
Start: 2005-08-31Updated: 2010-12-24

Phase 3

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
CompletedNCT00333840
Novartis PharmaceuticalsChronic Myelogenous Leukemia
Start: 2000-06-30End: 2012-03-31Updated: 2013-10-14
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)
Not yet recruitingCTIS2024-511496-14-00
Ascentage Pharma Group Inc.Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Target: 58Updated: 2025-07-07

Related Papers

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
New England Journal of Medicine2017-03-081212 citations
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
2008-02-06474 citations